Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 1029-1034

  N'Dri Yoman, Thérèse ^a,b   Anglaret, Xavier ^a,c   Messou, Eugène ^a   Attia, Alain ^b   Polneau, Sandrine ^a   Toni, Thomas ^d   Chenal, Henri ^d   Seyler, Catherine ^a   Gabillard, Delphine ^c   Wakasugi, Naomi ^e   Eholié, Serge ^f   Danel, Christine ^a,c  

^a Programme PAC CI   (Côte d’Ivoire)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

^c INSERM   (France)

^d Centre Integrée de Recherches Bioclinique d'Abidjan   (Côte d’Ivoire)

^e WASEDA UNIVERSITY   (Japan)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SCREENING TEST;

ADENINE; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COTE D'IVOIRE; CROSS-SECTIONAL STUDIES; DEOXYCYTIDINE; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREVALENCE; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 78651071056     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1641     Document Type: Article

References (24)

1. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9:25-39.
2. Piroth L, Sene D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007; 21:1323-1331.
3. Thio CL, Seaberg EC, Skolasky R, Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
4. Danel C, Moh R, Anzian A, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006; 42:29-35. (Pubitemid 43947943)
5. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479-1485.
6. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308. (Pubitemid 46883484)
7. Diop-Ndiaye H, Toure-Kane C, Etard JF, et al. C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008; 80:1332-1336. (Pubitemid 351897402)
8. Rouet F, Chaix ML, Inwoley A, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004; 74:34-40.
9. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006. (Updated 1 July 2006. Accessed 9 January 2009.) Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf
10. Lo Re V, III, Frank I, Gross R, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44:315-320. (Pubitemid 46328349)
11. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35:14-20.
12. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J Med Virol 2009; 81:406-412.
13. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001; 34:194-203. (Pubitemid 32591500)
14. Carreno V, Bartolome J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008; 18:139-157.
15. Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005; 34 Suppl 1:S15-S21.
16. Perez-Rodriguez MT, Sopena B, Crespo M, et al. Clinical significance of 'anti-HBc alone' in human immunodeficiency virus-positive patients. World J Gastroenterol 2009; 15:1237-1241.
17. Firnhaber C, Viana R, Reyneke A, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009; 13:488-492.
18. Shire NJ, Rouster SD, Stanford SD, et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44:309-314.
19. Nebbia G, Garcia-Diaz A, Ayliffe U, et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 2007; 79:1464-1471.
20. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009; 81:441-445.
21. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Eur J Clin Microbiol Infect Dis 1998; 17:6-13.
22. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20:1253-1260.
23. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-1690.
24. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349:995-996. (Pubitemid 27149806)